Secondary analysis of a stage IV NSCLC trial whose earlier report was retracted: add-on individualised homeopathy (n=51) vs placebo (n=47) was associated with higher global QoL at 9 and 18 weeks (p<0.001) and median survival of 435 vs 257 days (p=0.010).
Secondary analysisn = 98
Frass et al. Improved quality of life and prolonged survival with add-on homeopathic treatment in patients with non-small cell lung cancer: a prospective, randomized, placebo-controlled, double-blind, three-arm, multicenter study